Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.55 |
| ▸ | RELA | Q04206 | 5/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5601305 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4520862 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL10081129 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL5601052 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL14586680 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4713242 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4713236 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4713238 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL14459580 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL14459596 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574046-A | Method for preparing (1R,3S) -3-aminocyclopentanol hydrochloride | 深圳市华先医药科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-112574046-A | Method for preparing (1R,3S) -3-aminocyclopentanol hydrochloride | 深圳市华先医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-1537066-B1 | CYCLOPENTENONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | BIOGEM S C AR L (IT) | 2017-01-25 | — | — | EP | disclosed |
| US-7183440-B2 | Pharmaceutically useful compounds | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2007-02-27 | — | — | US | disclosed |
| US-7183440-B2 | Pharmaceutically useful compounds | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20060040869-A1 | Pharmaceutically useful compounds | BIOGEM S.C.A.R.L. (IT) | 2006-02-23 | — | — | US | disclosed |
| EP-1537066-A2 | IMPROVEMENTS IN PHARMACEUTICALLY USEFUL COMPOUNDS | Charterhouse Therapeutics Ltd. (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013077-A2 | CYCLOPENTANONE AND CYCLOPENTANONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040869-A1 | Pharmaceutically useful compounds | MC2R, CRKL, NPY2R | NFKB1 2975/4885NFKB2 2252/4885RELA 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.